Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-16673 vs Investigator's Choice in R/R CLL/SLL
NCT06970743Phase 3Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- May 2025
- Primary completion
- Nov 2029
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of catadegbrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-Free Survival by IRC at 23 months. Started May 2025; status: active, not recruiting.
02
Drugs
catadegbrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06970743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970743.